HCM

HUTCHMED China (HCM)

HUTCHMED China Limited

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:HCM

1 2 3 4 5 6 7 8 9 10 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/05/08	17 : 30	GlobeNewswire Inc.	HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee	NASDAQ:HCM	HUTCHMED China Limited
2024/04/26	21 : 30	GlobeNewswire Inc.	HUTCHMED Announces Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer Received by Takeda	NASDAQ:HCM	HUTCHMED China Limited
2024/04/05	17 : 30	GlobeNewswire Inc.	HUTCHMED Highlights Data to be Presented at AACR Congress 2024	NASDAQ:HCM	HUTCHMED China Limited
2024/04/02	13 : 30	GlobeNewswire Inc.	HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status	NASDAQ:HCM	HUTCHMED China Limited
2024/03/28	09 : 00	GlobeNewswire Inc.	HUTCHMED Announces Savolitinib sNDA Accepted in China for Treatment-Naïve or Previously Treated Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC	NASDAQ:HCM	HUTCHMED China Limited
2024/03/22	09 : 00	GlobeNewswire Inc.	HUTCHMED Initiates Registration Stage of the ESLIM-02 Phase II/III Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China	NASDAQ:HCM	HUTCHMED China Limited
2024/03/05	20 : 04	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:HCM	HUTCHMED China Limited
2024/02/28	20 : 47	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:HCM	HUTCHMED China Limited
2024/02/28	20 : 40	Edgar (US Regulatory)	Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]	NASDAQ:HCM	HUTCHMED China Limited
2024/02/28	20 : 30	GlobeNewswire Inc.	HUTCHMED Reports 2023 Full Year Results and Provides Business Updates	NASDAQ:HCM	HUTCHMED China Limited
2024/02/07	20 : 43	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:HCM	HUTCHMED China Limited
2024/02/07	09 : 00	GlobeNewswire Inc.	HUTCHMED Highlights Presentation of Phase III Data on Fruquintinib in Second-Line Gastric Cancer at ASCO Plenary Series Session	NASDAQ:HCM	HUTCHMED China Limited
2024/02/02	20 : 15	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:HCM	HUTCHMED China Limited
2024/02/02	17 : 30	GlobeNewswire Inc.	HUTCHMED Announces that Inmagene Exercises Option to License Two Drug Candidates as Part of Strategic Partnership	NASDAQ:HCM	HUTCHMED China Limited
2024/02/01	20 : 06	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:HCM	HUTCHMED China Limited
2024/02/01	17 : 30	GlobeNewswire Inc.	HUTCHMED to Announce 2023 Final Results	NASDAQ:HCM	HUTCHMED China Limited
2024/01/30	20 : 17	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:HCM	HUTCHMED China Limited
2024/01/30	13 : 53	GlobeNewswire Inc.	HUTCHMED Receives ELUNATE® (fruquintinib) Marketing Approval in Hong Kong for Treatment of Metastatic Colorectal Cancer	NASDAQ:HCM	HUTCHMED China Limited
2024/01/11	20 : 02	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:HCM	HUTCHMED China Limited
2024/01/11	09 : 00	GlobeNewswire Inc.	HUTCHMED Announces NDA Acceptance in China for Sovleplenib for the Treatment of Primary Immune Thrombocytopenia with Priority Review Status	NASDAQ:HCM	HUTCHMED China Limited
2023/12/29	20 : 04	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:HCM	HUTCHMED China Limited
2023/12/21	20 : 14	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:HCM	HUTCHMED China Limited
2023/12/13	20 : 04	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:HCM	HUTCHMED China Limited
2023/12/13	13 : 30	GlobeNewswire Inc.	HUTCHMED Announces Continued Inclusion of ELUNATE® (fruquintinib) and SULANDA® (surufatinib) in the National Reimbursement Drug List in China at Current Terms	NASDAQ:HCM	HUTCHMED China Limited
2023/12/13	09 : 00	GlobeNewswire Inc.	HUTCHMED Announces that it has Completed Enrollment of a Phase II/III Trial of Fruquintinib in Combination with Sintilimab for Advanced Renal Cell Carcinoma in China	NASDAQ:HCM	HUTCHMED China Limited
2023/12/07	20 : 03	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:HCM	HUTCHMED China Limited
2023/12/01	20 : 03	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:HCM	HUTCHMED China Limited
2023/12/01	09 : 00	GlobeNewswire Inc.	HUTCHMED Highlights Clinical Data to be Presented at 2023 ESMO Asia and ESMO Immuno-Oncology Congresses	NASDAQ:HCM	HUTCHMED China Limited
2023/11/30	20 : 09	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:HCM	HUTCHMED China Limited
2023/11/10	22 : 35	GlobeNewswire Inc.	Deutsche Bank ADR Investor Conference: Presentations Now Available for Online Viewing	NASDAQ:HCM	HUTCHMED China Limited